Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

- Establishing High-quality Pharmaceutical Logistics Service Systems - ...

As geopolitical tensions prompt global pharmaceutical giants to pivot away from China, India's Contract Development and ...

China's Livzon Pharmaceutical Group Inc. will spend VND5.73 trillion ($221 million) to acquire almost 65 per cent of ...

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

The China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.

On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...